RxDoctor Payments Data

Ralph Rayner, MD

Cardiovascular Disease · Melbourne, FLNPI 1114026994

Payments from drug & device makers

$749in general payments, 2019–2025

Across 37 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$246
  • Johnson & Johnson$163
  • Amgen$73
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$52
  • Amarin Pharma, Inc.$46
  • Boehringer Ingelheim$46
  • plus $123 from 4 others

What the payments were for

  • Food & beverage$749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$749 in reported general payments places this provider in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$259,531
Medicare patients
991
Services billed
3,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$371,663
XareltoRivaroxaban114$111,266
EntrestoSacubitril/Valsartan93$97,495
JardianceEmpagliflozin79$92,878
Dabigatran EtexilateDabigatran Etexilate Mesylate91$27,340
Repatha SureclickEvolocumab14$19,802
Rosuvastatin Calcium642$14,961
NexlizetBempedoic Acid/Ezetimibe12$7,170
Metoprolol Succinate336$6,674
Candesartan Cilexetil72$5,973
Atorvastatin Calcium292$4,851
Valsartan105$4,351
Amlodipine Besylate374$3,805
Chlorthalidone190$3,518
Olmesartan Medoxomil133$3,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$163$111,266114 claims
NovartisEntresto$246$97,49593 claims
Boehringer IngelheimJardiance$46$92,87879 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →